News

1st approved Symbicort generic, Breyna, now available in US

Breyna, a generic version of Symbicort (budesonide-formoterol), has been launched in the U.S. for eligible people with chronic obstructive pulmonary disease (COPD) and asthma. The inhaled medication — the first Symbicort generic to be approved by the U.S. Food and Drug Administration — will become immediately available…

Marpai, NuvoAir partner to provide virtual COPD care to members

Marpai, an artificial intelligence-powered administrator of employer health plans, is partnering with NuvoAir to provide virtual care for heart and lung conditions such as chronic obstructive pulmonary disease (COPD) to its health plan members and their families. “We are thrilled to offer NuvoAir to address the high-cost…

FDA asked to approve ensifentrine as COPD maintenance therapy

Verona Pharma has filed an application asking the U.S. Food and Drug Administration (FDA) to approve inhaled ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The regulatory submission “is a significant milestone towards our goal of bringing this potential first-in-class therapy to COPD patients…

COPD symptoms tend to worsen with outdoor air pollution: US study

People with chronic obstructive pulmonary disease (COPD) tend to experience worsening symptoms at times when levels of pollution in their community are higher, a new U.S. study indicates. “Our findings are consistent with a growing number of studies reporting adverse effects of community-level exposure to air pollution on respiratory…

Prompt treatment with Breztri Aerosphere lowers exacerbation risk

Prompt treatment with Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) after a moderate or severe chronic obstructive pulmonary disease (COPD) exacerbation can lower the risk of a future worsening episodes. That’s according to data by AstraZeneca, which markets Breztri Aerosphere, in the late-breaking abstract, “Exacerbations and Real-world Outcomes…